The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Novartis
Stock and Other Ownership Interests - Novartis
An open-label, multicenter, phase II study of ceritinib in patients with advanced ALK+ non-lung solid tumors and hematological malignancies (ASCEND-10).
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Janssen Oncology; Merck
Speakers' Bureau - Bayer
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); E-therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Menarini (Inst); Merck (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
Other Relationship - Bristol-Myers Squibb
 
Tae Min Kim
Research Funding - AstraZeneca
(OPTIONAL) Uncompensated Relationships - AstraZeneca/MedImmune; Bayer; Boryung; Novartis; Sanofi; Takeda; Voronoi Health Analytics
 
Sun Young Rha
Consulting or Advisory Role - Abbvie; Daiichi Sankyo; Eisai; Ipsen; MSD Oncology; Novartis
Speakers' Bureau - Ipsen; Lilly
Research Funding - ASLAN Pharmaceuticals; Bayer; Bristol-Myers Squibb; Cellid; Eisai; Immunome; medpacto; MSD Oncology; Roche/Genentech; Sillajen
 
Federico Longo
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Ferrer; Lilly; Merck; MSD; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Lilly; MSD; Roche; SERVIER
Travel, Accommodations, Expenses - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Ferrer; Lilly; Merck; MSD; Roche; Sanofi; SERVIER
 
Sith Sathornsumetee
No Relationships to Disclose
 
Shirong Zhang
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Yulia Hirschberg
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Barnali Pramanik
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Barbara D Wamil
No Relationships to Disclose
 
Igor Kiss
Honoraria - Amgen; Bristol-Myers Squibb; Merck Serono; Roche; SERVIER
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; SERVIER